The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

pyrazinoate     pyrazine-2-carboxylic acid

Synonyms: CHEMBL613, Pyrazinic acid, PubChem8602, SureCN23757, P56100_ALDRICH, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of pyrazinoate


High impact information on pyrazinoate


Chemical compound and disease context of pyrazinoate


Biological context of pyrazinoate


Anatomical context of pyrazinoate


Associations of pyrazinoate with other chemical compounds


Gene context of pyrazinoate


Analytical, diagnostic and therapeutic context of pyrazinoate


  1. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. Salfinger, M., Crowle, A.J., Reller, L.B. J. Infect. Dis. (1990) [Pubmed]
  2. Interaction between allopurinol and pyrazinamide. Lacroix, C., Guyonnaud, C., Chaou, M., Duwoos, H., Lafont, O. Eur. Respir. J. (1988) [Pubmed]
  3. Nitrilase-catalyzed production of pyrazinoic acid, an antimycobacterial agent, from cyanopyrazine by resting cells of Rhodococcus rhodochrous J1. Kobayashi, M., Yanaka, N., Nagasawa, T., Yamada, H. J. Antibiot. (1990) [Pubmed]
  4. Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure. Stamatakis, G., Montes, C., Trouvin, J.H., Farinotti, R., Fessi, H., Kenouch, S., Méry, J.P. Clin. Nephrol. (1988) [Pubmed]
  5. Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. Guggino, S.E., Aronson, P.S. J. Clin. Invest. (1985) [Pubmed]
  6. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Cheng, S.J., Thibert, L., Sanchez, T., Heifets, L., Zhang, Y. Antimicrob. Agents Chemother. (2000) [Pubmed]
  7. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Sun, Z., Zhang, Y. Antimicrob. Agents Chemother. (1999) [Pubmed]
  8. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. Bergmann, K.E., Cynamon, M.H., Welch, J.T. J. Med. Chem. (1996) [Pubmed]
  9. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Speirs, R.J., Welch, J.T., Cynamon, M.H. Antimicrob. Agents Chemother. (1995) [Pubmed]
  10. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? Heifets, L.B., Flory, M.A., Lindholm-Levy, P.J. Antimicrob. Agents Chemother. (1989) [Pubmed]
  11. Renal excretion of a slauretic-uricosuric agent (MK-196) and interaction with a urate-retaining drug, pyrazinoate, in the chimpanzee. Fanelli, G.M., Bohn, D.L., Zacchei, A.G. J. Pharmacol. Exp. Ther. (1977) [Pubmed]
  12. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. Barco, P., Cardoso, R.F., Hirata, R.D., Leite, C.Q., Pandolfi, J.R., Sato, D.N., Shikama, M.L., de Melo, F.F., Mamizuka, E.M., Campanerut, P.A., Hirata, M.H. J. Antimicrob. Chemother. (2006) [Pubmed]
  13. The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms. Sun, Z., Scorpio, A., Zhang, Y. Microbiology (Reading, Engl.) (1997) [Pubmed]
  14. Pharmacokinetics of pyrazinoyl-guanidine, 3-aminopyrazinoyl-guanidine and their corresponding pyrazinoic acid metabolites in humans and dogs. Passananti, G.T., Vesell, E.S., Jeszenka, E.V., Gelarden, R.T., Beyer, K.H. Pharmacology (1992) [Pubmed]
  15. Studies on pyrazinoylguanidine. 2. Comparative drug and dose effects on glucose and lipid metabolism in streptozotocin-induced diabetic rats. A-Rahim, Y.I., Beyer, K.H., Vesell, E.S. Pharmacology (1996) [Pubmed]
  16. Change in the transport of uric acid under the influence of pyrazinoic acid: in vitro studies with human and rabbit peritoneum. Czyźewska, K., Grzegorzewska, A., Knapowski, J. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. (1989) [Pubmed]
  17. Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids. Gurumurthy, P., Nair, N.G., Sarma, G.R. Indian J. Med. Res. (1980) [Pubmed]
  18. Effects of p-aminohippurate and pyrazinoate on urate excretion in Cebus monkeys. Perez-Gonzalez, M., Weiner, I.M. J. Pharmacol. Exp. Ther. (1984) [Pubmed]
  19. Effects of p-aminohippurate and pyrazinoate on the renal excretion of salicylate in the rat: a micropuncture study. Ferrier, B., Martin, M., Roch-Ramel, F. J. Pharmacol. Exp. Ther. (1983) [Pubmed]
  20. Urate and p-aminohippurate transport in the brush border membrane of the pig kidney. Werner, D., Martinez, F., Roch-Ramel, F. J. Pharmacol. Exp. Ther. (1990) [Pubmed]
  21. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. Zhang, Y., Scorpio, A., Nikaido, H., Sun, Z. J. Bacteriol. (1999) [Pubmed]
  22. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. Boshoff, H.I., Mizrahi, V., Barry, C.E. J. Bacteriol. (2002) [Pubmed]
  23. Functional analysis and molecular modeling of a cloned urate transporter/channel. Leal-Pinto, E., Cohen, B.E., Abramson, R.G. J. Membr. Biol. (1999) [Pubmed]
  24. Characteristics of urate influx in the rat nephron. Kramp, R.A., Lenoir, R.H. Am. J. Physiol. (1975) [Pubmed]
  25. Growth-promoting activity of pyrazinoic acid, a putative active compound of antituberculosis drug pyrazinamide, in niacin-deficient rats through the inhibition of ACMSD activity. Fukuwatari, T., Sugimoto, E., Shibata, K. Biosci. Biotechnol. Biochem. (2002) [Pubmed]
  26. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency. Lacroix, C., Tranvouez, J.L., Phan Hoang, T., Duwoos, H., Lafont, O. Arzneimittel-Forschung. (1990) [Pubmed]
  27. The effect of pyrazines on the metabolism of tryptophan and nicotinamide adenine dinucleotide in the rat. Evidence of the formation of a potent inhibitor of aminocarboxy-muconate-semialdehyde decarboxylase from pyrazinamide. Nasu, S., Yamaguchi, K., Sakakibara, S., Imai, H., Ueda, I. Biochim. Biophys. Acta (1981) [Pubmed]
WikiGenes - Universities